Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nalpropion Pharmaceuticals LLC has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners but 3 art units, indicating examiner dispersion with some art-unit overlap.
RAO, SAVITHA M is the busiest examiner, with 1 pending matter. The portfolio calls for multiple examiner-specific responses, while the repeated art-unit assignment may justify checking for shared technical or claim issues.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| RICCI, CRAIG D | 1 | 53.7% | +52.5% |
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.8% |
| PECKHAM, RICHARD GRANT | 1 | 68.3% | +35.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17336546 | Methods For Reducing Binge Or Compulsive Eating | IVANOVA, SVETLANA M | 9d |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | RICCI, CRAIG D | 34d |
| 17335646 | Compositions and Methods for Increasing Insulin Sensitivity | PECKHAM, RICHARD GRANT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17336546 | Methods For Reducing Binge Or Compulsive Eating | IVANOVA, SVETLANA M | 9d |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | RICCI, CRAIG D | 34d |
| 18731965 | Compositions And Methods For Reducing Major Adverse Cardiovascular Events | RAO, SAVITHA M | — |
| 17335646 | Compositions and Methods for Increasing Insulin Sensitivity | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1691 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18731965 | Compositions And Methods For Reducing Major Adverse Cardiovascular Events | RAO, SAVITHA M | 1691 | §102DP | Non-Final OA | — | Pending | Jun 03, 2024 |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | RICCI, CRAIG D | 1611 | §103§112Other | Final Rejection | 34d | Pending | Apr 11, 2022 |
| 17336546 | Methods For Reducing Binge Or Compulsive Eating | IVANOVA, SVETLANA M | 1627 | §102§112 | Non-Final OA | 9d | Pending | Jun 02, 2021 |
| 17335646 | Compositions and Methods for Increasing Insulin Sensitivity | PECKHAM, RICHARD GRANT | 1627 | §103§112Other | Non-Final OA | — | Pending | Jun 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNalpropion Pharmaceuticals LLC has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.
Savitha M Rao has the most, with 1 of Nalpropion Pharmaceuticals LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.